| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA899: Esketamine for treating major depressive disorder in adults at imminent risk for suicide |
|
Medicine details |
|
| Medicine name | esketamine (Spravato®) |
| Formulation | 28 mg nasal spray solution |
| Reference number | 3649 |
| Indication | Co-administered with oral antidepressant therapy, for treatment of adults with a moderate to severe episode of Major Depressive Disorder, as acute short-term treatment, for the rapid reduction of depressive symptoms, which according to clinical judgement constitute a psychiatric emergency |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 08/07/2021 |
| NICE guidance | TA899: Esketamine for treating major depressive disorder in adults at imminent risk for suicide |